EA201290720A1 - Двузамещенные производные пиридина в качестве противораковых средств - Google Patents

Двузамещенные производные пиридина в качестве противораковых средств

Info

Publication number
EA201290720A1
EA201290720A1 EA201290720A EA201290720A EA201290720A1 EA 201290720 A1 EA201290720 A1 EA 201290720A1 EA 201290720 A EA201290720 A EA 201290720A EA 201290720 A EA201290720 A EA 201290720A EA 201290720 A1 EA201290720 A1 EA 201290720A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenylene
lower alkylene
facilities
cancer
double
Prior art date
Application number
EA201290720A
Other languages
English (en)
Other versions
EA026042B1 (ru
Inventor
Хидеки Такасу
Сигеказу Фудзита
Синия Охцука
Тосиюки Хиросе
Йосуке Сато
Сатоси Ямада
Кейсуке Миядзима
Кодзи Сакаи
Ютака Кодзима
Казуо Секигути
Ясуо Янагихара
Такаси Судзуки
Хидео Танака
Казухиса Сугияма
Мицухиро Окуно
Такуми Сумида
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA201290720A1 publication Critical patent/EA201290720A1/ru
Publication of EA026042B1 publication Critical patent/EA026042B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Настоящее изобретение относится к новому соединению, имеющему превосходный противоопухолевый эффект. Соединение согласно настоящему изобретению представлено следующей общей формулой (1)в которой Rи Rобозначают арил или подобное; А обозначает низший алкилен; кольцо Х обозначает в случае необходимости замещенный арилен; Е обозначает связь или низший алкенилен; кольцо Y обозначает в случае необходимости замещенный гетероциклоалкилен, содержащий один или более атомов азота, один из которых присоединен к смежной карбонильной группе; G обозначает -NH-G-, -N(низший алкил)-G-, -NH-CH-G-, -N(низший алкил)-CH-G- или -CH-G- [причем Gсвязывается с R, G-Rобозначает связь-R, фенилен-G-R, фенилен-G-O-R, фенилен-G-NH-R, фенилен-G-N(низший алкил)-Rили хинолиндиил-O-R, причем фенилен указанных фениленсодержащих групп может быть замещен одним или более заместителями; С-Rобозначает -O-низший алкилен-Rили подобное; G-O- обозначает низший алкилен -О- или подобное; Gобозначает низший алкилен; Gобозначает низший алкилен].
EA201290720A 2010-01-29 2011-01-28 Двузамещенные производные пиридина в качестве противораковых средств EA026042B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29963110P 2010-01-29 2010-01-29
US35972910P 2010-06-29 2010-06-29
PCT/JP2011/052302 WO2011093524A1 (en) 2010-01-29 2011-01-28 Di - substituted pyridine derivatives as anticancers

Publications (2)

Publication Number Publication Date
EA201290720A1 true EA201290720A1 (ru) 2013-02-28
EA026042B1 EA026042B1 (ru) 2017-02-28

Family

ID=43797869

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290720A EA026042B1 (ru) 2010-01-29 2011-01-28 Двузамещенные производные пиридина в качестве противораковых средств

Country Status (27)

Country Link
US (1) US8722663B2 (ru)
EP (1) EP2528897B9 (ru)
JP (1) JP5335932B2 (ru)
KR (1) KR101411030B1 (ru)
CN (1) CN102791690B (ru)
AR (1) AR080057A1 (ru)
AU (1) AU2011211306B2 (ru)
CA (1) CA2788073A1 (ru)
CO (1) CO6561817A2 (ru)
DK (1) DK2528897T3 (ru)
EA (1) EA026042B1 (ru)
ES (1) ES2521016T3 (ru)
HK (1) HK1178523A1 (ru)
HR (1) HRP20141190T1 (ru)
IL (1) IL221146A (ru)
MX (1) MX2012008391A (ru)
MY (1) MY160875A (ru)
NZ (1) NZ601794A (ru)
PL (1) PL2528897T3 (ru)
PT (1) PT2528897E (ru)
RS (1) RS53705B1 (ru)
SG (1) SG182663A1 (ru)
SI (1) SI2528897T1 (ru)
SM (1) SMT201500007B (ru)
TW (1) TWI404713B (ru)
UA (1) UA107692C2 (ru)
WO (1) WO2011093524A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013047223A (ja) * 2011-07-28 2013-03-07 Otsuka Pharmaceut Co Ltd 医薬
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 및 alk2 억제제 및 이들의 사용 방법
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
EP3816155A1 (en) * 2013-08-23 2021-05-05 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AR102094A1 (es) * 2014-09-25 2017-02-01 Araxes Pharma Llc Inhibidores de proteínas kras con una mutación g12c
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Rasの阻害剤をスクリーニングするための方法
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
CN112812781B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301880A (ja) * 1985-09-03 1988-12-08 Otsuka Pharmaceut Co Ltd 5−フルオロウラシル誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
US6262088B1 (en) * 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2002226429A (ja) * 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
MX2007001215A (es) * 2004-08-06 2007-04-17 Otsuka Pharma Co Ltd Compuestos aromaticos.
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
ZA200804445B (en) * 2005-12-05 2009-11-25 Otsuka Pharma Co Ltd Diarylether derivatives as antitumor agents
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US20100136509A1 (en) 2007-07-02 2010-06-03 Alden Mejer System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
DE202009007345U1 (de) * 2009-05-22 2009-09-10 Schebo (R) . Biotech Ag Neue Pharmazeutika und Arzneimittelzubereitungen

Also Published As

Publication number Publication date
AR080057A1 (es) 2012-03-07
ES2521016T3 (es) 2014-11-12
US8722663B2 (en) 2014-05-13
AU2011211306B2 (en) 2016-07-07
MY160875A (en) 2017-03-31
US20120283242A1 (en) 2012-11-08
MX2012008391A (es) 2012-08-15
EA026042B1 (ru) 2017-02-28
CA2788073A1 (en) 2011-08-04
WO2011093524A9 (en) 2011-12-01
SG182663A1 (en) 2012-08-30
KR20120065268A (ko) 2012-06-20
JP5335932B2 (ja) 2013-11-06
HRP20141190T1 (hr) 2015-01-30
JP2012525324A (ja) 2012-10-22
PT2528897E (pt) 2014-11-12
AU2011211306A1 (en) 2012-08-16
NZ601794A (en) 2014-04-30
CN102791690A (zh) 2012-11-21
IL221146A (en) 2015-11-30
HK1178523A1 (en) 2013-09-13
CN102791690B (zh) 2015-12-02
UA107692C2 (ru) 2015-02-10
DK2528897T3 (en) 2014-12-08
PL2528897T3 (pl) 2015-03-31
EP2528897A1 (en) 2012-12-05
RS53705B1 (en) 2015-04-30
SMT201500007B (it) 2015-03-05
CO6561817A2 (es) 2012-11-15
TW201136912A (en) 2011-11-01
KR101411030B1 (ko) 2014-06-30
EP2528897B9 (en) 2015-09-09
EP2528897B1 (en) 2014-10-15
TWI404713B (zh) 2013-08-11
WO2011093524A1 (en) 2011-08-04
SI2528897T1 (sl) 2015-02-27

Similar Documents

Publication Publication Date Title
EA201290720A1 (ru) Двузамещенные производные пиридина в качестве противораковых средств
DE502008001409D1 (de) Bisamid-zinkbasen
MY169348A (en) Fuel compositions
IN2014CN03976A (ru)
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
MY166864A (en) Fuel compositions
WO2009057811A3 (en) Heterocyclic compound and pharmaceutical composition thereof
CY1114452T1 (el) Ενωσεις πυρρολιου
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
MX346746B (es) Compuestos de anillo indeno-fusionados.
MX2014000937A (es) Compuesto de amidina o sal del mismo.
CO6320143A1 (es) Nuevos derivados dihidroindolonas su procedimeinto de preparacion y composiciones farmaceuticas que los contienen
BR112014004523A2 (pt) composto e composição aromatizante
EA201590315A1 (ru) Средства и способ лечения солидных опухолей
EA201170097A1 (ru) Замещенные трициклические производные против нейродегенеративных заболеваний
GB2470170A (en) Dithienothiophene derivatives
EP2612848A4 (en) CYCLIC AMIDE DERIVATIVE
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
PH12014502108A1 (en) Polyamide compositions with improved optical properties
IN2014DN08653A (ru)
BR112018000725A2 (pt) ?utilização de composições de moldagem termoplástica, artigo moldado e composição de moldagem termoplástica?
EA201390323A1 (ru) Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака
JO3082B1 (ar) مشتق بيروليدين-3- يل حمض خليك
CY1115784T1 (el) Παραγωγα δι-υποκατεστημενης πυριδινης ως αντικαρκινικα

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU